Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |